Squalamine on Trial
Squalamine may have fascinating origins – originally derived from the livers of the dogfish shark – but as a treatment for wet AMD it has so far failed to have any “bite.” An antiangiogenic steroid, this small molecule drug has been shown to stop the growth of abnormal blood vessel development and reduce vascular endothelial growth factor (VEGF), showing potential in cancer therapies as well as in treatment for macular diseases.
Initial trials discovered that it inhibited neovascularization in the iris when injected intravenously, and was found to induce regression of retinopathy in mouse models.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.